Safety and pharmacokinetics of bapineuzumab in a single ascending‐dose study in <scp>J</scp>apanese patients with mild to moderate <scp>A</scp>lzheimer's disease

Abstract

Plasma β-amyloidx-40 levels increased with increasing doses of bapineuzumab. Bapineuzumab was safe and well tolerated at all doses in Japanese patients with mild to moderate Alzheimer's disease. Geriatr Gerontol Int 2016; 16: 644-650.